Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Grande Portage Applies for Road Easement from State...
OPINION — Goldenomics 104: Trump’s Tariffs and Gold
Gold Price Rises as Powell Boosts Rate Cut...
Crypto Market Update: World Liberty Gets Coinbase Approval...
Cracker Barrel shares plummet after pushback on new...
FPX Nickel Joins Mining Association of Canada and...
West High YieldResources Ltd. Announces Exercise of Options...
NATO Defense Spending Pledge Puts Spotlight on Platinum...
Trump, Rio Tinto Push for Copper as Court...
Alice Queen
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Investing

Cleo Commences U.S. Clinical Trials

by admin September 6, 2024
September 6, 2024
Cleo Commences U.S. Clinical Trials

Ovarian cancer diagnostics company, Cleo Diagnostics Limited (ASX:COV) (CLEO, or the Company) is pleased to confirm the commencement of U.S. clinical trials for its ovarian cancer diagnostic blood test.

Highlights

U.S. clinical trials commenced with first patients enrolled over 8 recruitment centresTrial will validate the use of CLEO’s ovarian cancer blood test for the U.S. marketPathway set toward FDA submission in CY2025.

Commencement of U.S. Clinical Trials

CLEO’s pivotal FDA-enabling clinical trial has commenced in the United States, with first patients recruited into the study. The trial is designed to benchmark CLEO’s technology, with recruitment targeting a minimum of 500 patients with diversity representative of the U.S. population. The data collected will underpin a submission to the Food and Drug Administration (FDA) seeking approval for clinical use of CLEO’s ovarian cancer detection blood test in the world’s largest diagnostic market.

Eight participating medical institutions, located across 6 U.S. states, are currently recruiting patients. Eligible patients at these sites will be identified by their primary physician and given the opportunity to participate during their consultation. Additional sites may also be included as the trial progresses.

Commenting on the commencement of U.S. clinical trials, CLEO Chief Executive, Richard Allman, said:

“Commencement of our U.S. trials confirm a significant milestone for CLEO and sets a clear pathway now for our planned entry into the U.S. market.

We have already demonstrated that CLEO’s ovarian cancer blood test is highly accurate, can detect early-stage cancer, and importantly is significantly better than clinical tools used today. This gives us confidence in moving through the trial activities to enable our FDA submission.

It is important to note that no diagnostic test exists today for ovarian cancer. Diagnosis can only be made after surgery. The opportunity in front of us is immense and CLEO is well positioned and funded to achieve access into our initial pre-surgery test market.”

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Arcadium Halts Mount Cattlin Expansion, Plans Transition to Care and Maintenance
next post
Horizon Minerals

You may also like

Endeavour on Track to Meet Gold Guidance, Expects...

August 3, 2024

Metals Exploration Eyes Condor Gold, Calibre Mining Denies...

December 3, 2024

Stardust Power Announces Year End 2024 Financial Results

March 28, 2025

4 Platinum Uses for Investors to Know (Updated...

December 18, 2024

Highly successful first milling campaign completed

March 20, 2025

World Copper Announces Corporate Update Webinar

August 24, 2024

Gary Wagner: Gold Thriving Amid Uncertainty, Price Uptrend...

April 12, 2025

BPH Energy LimitedPEP11 Offshore Petroleum Joint Venture Update

March 18, 2025

2 Biggest Medical Device ETFs in 2025

February 18, 2025

Edjudina Gold Project, WA – Permitting Application to...

March 26, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Grande Portage Applies for Road Easement from State of Alaska

      August 23, 2025
    • OPINION — Goldenomics 104: Trump’s Tariffs and Gold

      August 23, 2025
    • Gold Price Rises as Powell Boosts Rate Cut Expectations in Jackson Hole Speech

      August 23, 2025
    • Crypto Market Update: World Liberty Gets Coinbase Approval with Stablecoin Listing

      August 23, 2025
    • Cracker Barrel shares plummet after pushback on new logo, brand refresh

      August 23, 2025
    Promotion Image

    banner ads

    Categories

    • Business (824)
    • Economy (829)
    • Investing (2,678)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved